Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Ironwood Pharmaceuti (NQ: IRWD )

4.445 +0.105 (+2.42%)
Streaming Delayed Price Updated: 2:03 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuti

< Previous 1 2 3 4 5 6 Next >
Top 4 Health Care Stocks You May Want To Dump In February
As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
A Preview Of Ironwood Pharmaceuticals's Earnings
Via Benzinga
Chart Of The Day: Ironwood Pharma - Gastrointestinal Products
Via Talk Markets
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Earnings Preview For Ironwood Pharmaceuticals
Via Benzinga
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to... 
Via Newsfile
Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Why Terran Orbital Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares jumped 124.2% to $0.1697 after falling 15% on Monday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
Via Benzinga
Orchestra BioMed, Vital Farms And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround
Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned. 
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Why Ironwood Pharmaceuticals Stock Bumped Higher Today
Investors indicated approval of the company's upcoming $1 billion asset purchase. 
Via The Motley Fool
Ironwood Scoops Up Gastrointestinal Diseases Player For $1B
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) has agreed to acquire VectivBio Holding AG (NASDAQ: VECT) for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.